Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Sarah P. Blagden(Churchill Hospital), Hani Gabra(Royal Children's Hospital), Anne Hamilton(Royal Women's Hospital), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Michelle DeSilvio(Newark Beth Israel Medical Center), Linda Mileshkin(Peter MacCallum Cancer Centre), Tarek Meniawy(St John of God Subiaco Hospital), Euan A. Stronach(Age UK), Agnieszka Michael(University of Surrey), Eleni Frangou(Nuffield Orthopaedic Centre), Jeffrey C. Goh(The University of Queensland), Alla Lisyanskaya(City Clinical Oncology Center), Prashanth Gopalakrishna(Novartis (Switzerland)), Shirley Wong(Western Hospital)
Cited by 66
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k